Arthritis Research Canada at
Lupus 2025
May 22
Developing and evaluating a laboratory-based frailty index (FI-LAB) for the prediction of long-term health outcomes in systemic lupus erythematosus. #O013
Prior studies in older adults have shown that frailty can be identified using routinely collected laboratory test results. We have created the first laboratory-based frailty index (FI-Lab) for identifying frailty among people living with systemic lupus and found that it predicted well future health outcomes. This can serve as a tool for screening people at high risk, so early intervention may improve health outcomes.
Research Team: Burns G, Legge A
Improvements observed in skin and joint manifestations of systemic lupus erythematosus with dapirolizumab pegol treatment: results from a phase 3 trial. #O009
This study found that a new medication called dapirolizumab pegol helped improve skin and joint symptoms in people with lupus better than standard treatment alone. After 48 weeks, more patients on dapirolizumab pegol had at least a 50% improvement in skin rashes and joint pain or swelling. This research shows us that dapirolizumab pegol could be a promising new option for better managing lupus symptoms.
Research Team: Askanase A, Clarke AE, Gladman DD, Werth VP, Yusof Y, Gaiha-Rohrbach J, Jimenez T, Koch ED, Koncz A, Nelde A, Van Vollenhoven R.
